Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Shun Lu, Jie Wang, Nong Yang, Jie Wang, Lijuan Chen, Lin Wu, XingYa Li, Longhua Sun, Yongfeng Yu, Bo Jin, L. Yang, Y. Guo, Haipeng Xu, T. Yi, Aiping Zeng, X. Dong, Jianhua Chen, Ziping Wang, Hongrui Niu, Ying Cheng, Pan P, Pengbo Deng, Hongming Pan, Xuhong Min, Jun Bai, L. Liu, Tongmei Zhang, Juan Li, Songhua Fan, Michael M. Shi, Tony Mok, WeiGuo Su, Shun Lu, Jie Wang, Nong Yang, Shun Lu, Lijuan Chen, Lin Wu, XingYa Li, Longhua Sun, Yongfeng Yu, Bo Jin, L. Yang, Y. Guo, Haipeng Xu, T. Yi, Aiping Zeng, X. Dong, Jianhua Chen, Ziping Wang, Hongrui Niu, Ying Cheng, Pan P, Pengbo Deng, Hongming Pan, Xuhong Min, Jun Bai, L. Liu, Tongmei Zhang, Juan Li, Songhua Fan, Michael M. Shi, Tony Mok, WeiGuo Su, Feng Ye, Xianling Liu, Jianhua Shi, Jiwei Liu, Qisen Guo, Weihua Yang, Junfang Tang, Shundong Cang, Ou Jiang, Jian Fang, Guohua Yu, Lijun Wang, Xibin Zhuang, Zhigang Han, Yiping Zhang, Zhengbo Song, Baogang Liu, Buhai Wang, Jianying Zhou, Wei Gu, Hongcheng Wu, Zhiwei Lu, Yan Yang, Wen Dong, Xiuhua Fu, Youling Gong, Jinhuo Lai, Ping Sun, Yingying Du, Zhihua Liu, Diansheng Zhong, Kaihua Lu, Jianghong Wang, Zhaohong Chen, Xiujie Cui, Zhengxiang Han